Actively Recruiting
Prospective Evaluation of Silk Fibroin Incision Dressings in ACL Reconstruction
Led by NYU Langone Health · Updated on 2026-05-08
100
Participants Needed
1
Research Sites
37 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to compare the incidence of early postoperative skin complications including allergic contact dermatitis, blistering, and erythema between silk fibroin incision dressings and cyanoacrylate closure in patients undergoing anterior cruciate ligament reconstruction.
CONDITIONS
Official Title
Prospective Evaluation of Silk Fibroin Incision Dressings in ACL Reconstruction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 14 to 60 years
- Scheduled for primary or revision anterior cruciate ligament reconstruction
- Able and willing to provide informed consent (18 years or older) or assent with parental/guardian permission (ages 14-17)
- Able and willing to comply with all study procedures and follow-up visits
You will not qualify if you...
- Active skin conditions near the surgical site such as eczema, psoriasis, dermatitis, or open wounds
- Immunocompromised conditions like uncontrolled HIV, chemotherapy, or chronic corticosteroid use
- Known or suspected allergy to silk fibroin or cyanoacrylate adhesives
- Uncontrolled diabetes with recent HbA1c of 8.0 or higher, if available
- Active systemic infection at enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
Research Team
L
Layne Estes
CONTACT
E
Eric J. Straus, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here